Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial
Developmental Medicine & Child Neurology · 2025-06 · 67 (6) · 750-757
DOI: 10.1111/dmcn.16199 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 04.12.2024. Verfasst von Yanick J Crow und 8 weiteren Autor:innen. Beteiligte Einrichtung: MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. Hauptthemen laut MEDLINE: Autoimmune Diseases of the Nervous System, Nervous System Malformations, Reverse Transcriptase Inhibitors, Zidovudine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health.
Abstract (Originalsprache)
Aim
To extend the findings of a previous clinical trial suggesting combined abacavir (ABC), lamivudine (3TC), and zidovudine (AZT) reduces type I interferon (IFN) signalling in Aicardi–Goutières syndrome (AGS).
Method
This was an open label, non‐placebo‐controlled phase II clinical trial (NCT04731103) in patients less than 16 years with any of five AGS genotypes. The effect of ABC or 3TC individually, or of combined ABC + 3TC + AZT, on IFN‐stimulated gene (ISG) expression (primary outcome) and IFN‐alpha protein (secondary outcome) in blood was assessed.
Results
Thirteen patients were recruited. Compliance was poor in the ABC + 3TC + AZT arm. No statistically significant effects were observed with ABC or 3TC, or with ABC + 3TC + AZT over 6 weeks. A statistically significant reduction of ISG expression was recorded after 3 weeks of ABC + 3TC + AZT, which was not mirrored by changes in IFN‐alpha protein.
Interpretation
There is insufficient evidence that ABC or 3TC is either effective or ineffective in reducing type I IFN signalling in AGS over 6 weeks. The effect of ABC + 3TC + AZT at 3 weeks supports data from a previous clinical trial of the effect of ABC + 3TC + AZT in reducing type I IFN signalling, although there was insufficient evidence of an effect at 6 weeks. Time to local research and development (R&D) approval, and to sponsor authorization after R&D approval, severely limited patient recruitment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
- Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.
- Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
- Department of Genomic Medicine, St Marys Hospital, Manchester Foundation Trust, Manchester, UK.
- Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Infection, Immunity and Inflammation Department, University College London Great Ormond Street Institute of Child Health, London, UK.
ORCID-Profile: Yanick J Crow
Förderung
- Medical Research Council
- Department of Health
Zitieren
APA
Crow, Y. J., Briggs, T. A., Eleftheriou, D., Parida, A., Battison, C., Giddings, A., Kennel, T., Parker, R. A., & AGS‐RTIs Study Group (2025). Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial. Developmental Medicine & Child Neurology, 67(6), 750-757. https://doi.org/10.1111/dmcn.16199
Vancouver
Crow YJ, Briggs TA, Eleftheriou D, Parida A, Battison C, Giddings A, et al. Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial. Developmental Medicine & Child Neurology. 2025;67(6):750-757. doi:10.1111/dmcn.16199
BibTeX
@article{Crow2025,
author = {Crow, Yanick J and Briggs, Tracy A and Eleftheriou, Despina and Parida, Amitav and Battison, Claire and Giddings, Annabel and Kennel, Titouan and Parker, Richard A and AGS‐RTIs Study Group, AGS‐RTIs Study Group},
title = {Reverse transcriptase inhibitors in Aicardi–Goutières syndrome: A crossover clinical trial},
journal = {Developmental Medicine & Child Neurology},
year = {2025},
volume = {67},
number = {6},
pages = {750--757},
doi = {10.1111/dmcn.16199}
}
EUVIMED